Aurobindo Pharma USA Inc. Initiates Nationwide Recall of Nebivolol Tablets Over Nitrosamine Impurity Exceeding FDA Limits
Aurobindo Pharma USA Inc. has initiated a Class II recall of Nebivolol Tablets (2.5 mg) across the USA due to N-Nitroso Nebivolol, a nitrosamine impurity, exceeding acceptable intake limits. This CGMP deviation poses significant regulatory and supply chain risks for procurement and regulatory affairs teams, necessitating immediate assessment of existing stock and sourcing strategies for hypertension treatments.
FDA-Mandated Recall: Aurobindo's Nebivolol Tablets Exceed Nitrosamine Limits
Aurobindo Pharma USA Inc., operating from East Windsor, New Jersey, has initiated a voluntary Class II recall (D-0149-2025) for specific lots of its Nebivolol Tablets, 2.5 mg. This critical action, initiated on December 6, 2024, stems from identified Current Good Manufacturing Practice (CGMP) deviations, specifically the presence of N-Nitroso Nebivolol, a Nitrosamine Drug Substance Related Impurity (NDSRI), at levels exceeding the FDA's acceptable intake (AI) limit. The affected product, distributed nationwide in the USA, includes 30-count bottles with NDC 59651-137-30, from Lot Numbers NB0224001A and NB0224001B, both with an expiration date of April 2027. The ongoing recall underscores a significant quality control failure within the supply chain for this critical hypertension medication. For procurement directors and regulatory affairs heads, this event signals a direct threat to product availability and patient safety. The presence of NDSRIs, known for their genotoxic and carcinogenic potential, necessitates immediate action to remove affected product from the market. This recall, while firm-initiated, highlights a systemic issue in ensuring product quality, which can lead to severe reputational damage and substantial financial penalties. Companies relying on Aurobindo Pharma for Nebivolol must assess their inventory and distribution channels without delay to comply with the recall and safeguard patient health.
Aurobindo's US Distribution Network and Nebivolol Product Profile
Aurobindo Pharma USA Inc., located at 279 Princeton Hightstown Road, East Windsor, NJ 08520, serves as the recalling firm and primary distributor for the affected Nebivolol Tablets within the United States. While the specific manufacturing facility for the Nebivolol API or finished dosage form is not detailed in the recall notice, the US entity bears responsibility for the quality and compliance of products distributed under its name. Nebivolol Hydrochloride is a beta-blocker primarily prescribed for the treatment of hypertension, making its consistent and safe supply crucial for patient management across the country. The recalled product is a human prescription drug, administered orally. The recall impacts multiple product NDC codes, including 59651-137, 59651-138, 59651-139, and 59651-140, indicating a broader potential for supply disruption across various dosage strengths and package configurations, although the specific recall notice highlights the 2.5 mg, 30-count bottles. This nationwide distribution pattern means that healthcare providers, pharmacies, and ultimately patients across all states are potentially affected. Procurement teams must understand that a recall at the distribution level reflects directly on the entire supply chain's integrity, demanding scrutiny of all products sourced from this distributor, regardless of their manufacturing origin.
Supply Chain Exposure: Impact on Hypertension Treatment and Market Availability
The nationwide recall of Aurobindo Pharma USA Inc.'s Nebivolol Tablets, 2.5 mg, creates immediate supply chain vulnerabilities for healthcare systems and pharmacies relying on this specific generic formulation for hypertension management. Nebivolol, with its unique pharmacological profile, is a critical component in many treatment regimens. The affected lots (NB0224001A and NB0224001B, Exp. Date 04/2027) represent a tangible gap in the market that procurement teams must address rapidly. The product's various package NDCs, such as 59651-137-30 and 59651-137-90, suggest widespread availability, amplifying the recall's impact. Business development executives should recognize this as an opportunity for competitors to capture market share, but also as a warning regarding the pervasive challenge of nitrosamine impurities. For supply chain VPs, the immediate concern is ensuring continuity of care for patients currently on Nebivolol. This necessitates identifying alternative sources, assessing their qualification status, and managing potential price volatility due to sudden demand shifts. The recall's Class II classification, indicating that the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote, still mandates swift action to protect patient trust and avoid potential liability.
Mitigating Nitrosamine Impurity Risks: A Proactive Supply Chain Strategy
The recurring issue of Nitrosamine Drug Substance Related Impurities (NDSRIs) like N-Nitroso Nebivolol highlights a persistent challenge across the global pharmaceutical supply chain. This Aurobindo recall serves as a stark reminder for procurement directors and regulatory affairs heads to implement robust, proactive strategies for impurity control. Simply reacting to recalls is insufficient; a comprehensive approach involves stringent supplier qualification, enhanced analytical testing protocols for both raw materials and finished products, and continuous monitoring of regulatory guidance on nitrosamine limits. Companies must demand full transparency from their Active Pharmaceutical Ingredient (API) and excipient suppliers regarding manufacturing processes and impurity profiles. This includes conducting thorough audits and requiring detailed Certificates of Analysis that specifically address potential nitrosamine formation. Establishing diversified sourcing strategies is paramount, reducing reliance on single suppliers and ensuring geographic redundancy. While specific alternative suppliers for Nebivolol are not detailed in the available intelligence, the market for generic beta-blockers is competitive. Procurement teams should proactively identify and qualify multiple suppliers to build resilience against such quality-driven disruptions, minimizing the commercial impact of future recalls and maintaining consistent patient access to essential medicines.
Regulatory Outlook: Expectations for Aurobindo's Remediation and Future Compliance
The "Ongoing" status of this recall (D-0149-2025) indicates that Aurobindo Pharma USA Inc. is actively managing the retrieval of affected Nebivolol Tablets from the market. However, the underlying CGMP deviations that led to the presence of N-Nitroso Nebivolol above acceptable limits will be subject to intense scrutiny by the FDA. As a firm-initiated voluntary recall, Aurobindo is expected to conduct a thorough root cause analysis to identify precisely how the NDSRI formed or was introduced into the product. This analysis must extend beyond the immediate product to encompass manufacturing processes, raw material sourcing, and quality control systems. Regulatory affairs heads should anticipate that the FDA will require a comprehensive Corrective and Preventive Action (CAPA) plan. This plan must detail specific, verifiable steps to prevent recurrence of nitrosamine contamination, including process adjustments, enhanced testing methodologies, and updated quality management systems. Failure to adequately address these CGMP deviations could escalate into further regulatory actions, potentially including a formal FDA Warning Letter, increased import alerts for products from associated manufacturing sites, or even consent decrees. Proactive engagement with the FDA and demonstrating a robust remediation strategy are critical for Aurobindo to mitigate long-term regulatory and commercial repercussions.